Avita Medical Ltd (RCEL)

[inversor86]

Avita Strengthens Board

Australia, 19 October 2012— Regenerative medicine company Avita Medical Ltd. (ASX: AVH), (OTC:
AVMXF), (OTCQX:AVMXY) announced that further to ASX announcements on 5 September 2012 and
16 October 2012 and following today’s Shareholder Meeting it is pleased to announce the
appointments of Jeremy Curnock Cook and Matt McNamara to the board of Avita Medical.  The
strengthening of Avita’s board follows the company’s successful capital raising of A$10.3m.
Avita Medical’s Chairman, Dalton Gooding stated the appointments of Mr Curnock Cook and Mr
McNamara further strengthen Avita’s board.
“I am delighted that both Jeremy and Matt have been appointed as directors of Avita Medical and I
extend a warm welcome on behalf of the board,” Mr Gooding said.
“We look forward to drawing on the extensive experience that both Jeremy and Matt have in
Biotechnology and Healthcare as we continue to increase our ReCell
®
Spray-On Skin
®
sales.”
Mr Curnock Cook is currently on a number of boards of International Healthcare and Biotechnology
companies.  Jeremy is the former head of the life science private equity team at Rothschild Asset
Management, was responsible for the launch of the first dedicated biotechnology fund for the
Australian market and the launch of a joint venture with Johnson & Johnson Development
Corporation for the creation of Healthcare Ventures, an investment vehicle dedicated to seed stage
investments in Europe, as well as the conception and launch of the International Biotechnology
Trust (IBT).  
Mr McNamara is currently the Chief Investment Officer and Fund Manager of Octa Phillip
Bioscience Managers.   Matt has over 23 years experience in the Healthcare & Medical Sciences
sector. After initially being a Molecular Biology Research Assistant, Matt spent 11 years in Sales &
Marketing, and General Management with Merck & Co. and Johnson and Johnson Medical Pty. Ltd.
respectively. He has served as SVP Business Development for a University of Sydney spin out,
eBioinformatics Inc. and was CEO of a Life Sciences Venture Capital fund, SciCapital Pty. Ltd.  
The board would also like to thank Dr Paul Watt who has retired from the board of Avita Medical
effective immediately.  The board would like to acknowledge Dr Watt’s extensive contribution that
he has made over a 10 year period including 6 years as a director of pre-merger company Visiomed
Limited.  Dalton Gooding stated, “The board wishes Dr Watt all the very best and success with his
future endeavours.”

http://member.afraccess.com/media?id=CMN://6A609022&filename=20121019/AVH_01345391.pdf